Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $158.8M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $60.5K in total
- 5
- 13F holdersQ2 2026, +5 vs. previous quarter
- 103
- 13F valueReported value at the end of Q2 2026
- $158.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BCYC, Q2 2026
No superinvestor reported holding BCYC at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Bicycle Therapeutics PLC insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Perry Jennifer ScottChief Operating Officer | SSale | −1.41K | $4.29 | −$6.05K | −1.5%91.1K after | 3 lots10b5-1 |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Skynner MichaelCHIEF SCIENTIFIC OFFICER | SSale | −2.39K | $4.28 | −$10.2K | −1.5%157.2K after | 2 lots |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Lee KevinCHIEF EXECUTIVE OFFICER | SSale | −7.64K | $4.28 | −$32.7K | −1.3%603.7K after | 2 lots |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | SSale | −1.76K | $4.28 | −$7.53K | −1.8%94.4K after | 2 lots |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Thompson Travis AlvinChief Financial Officer | SSale | −923 | $4.27 | −$3.95K | −1.4%64.4K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Perry Jennifer ScottChief Operating Officer | SSale | −1.41K | $4.94 | −$6.96K | −1.5%92.5K after | 3 lots10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | SSale | −1.77K | $4.93 | −$8.74K | −1.8%96.1K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Thompson Travis AlvinChief Financial Officer | SSale | −901 | $4.93 | −$4.44K | −1.4%65.4K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Lee KevinCHIEF EXECUTIVE OFFICER | SSale | −7.68K | $4.94 | −$38.0K | −1.2%611.3K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Skynner MichaelCHIEF SCIENTIFIC OFFICER | SSale | −2.40K | $4.94 | −$11.9K | −1.5%159.6K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Bicycle Therapeutics PLC at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 10,885,357 | $46.2M | 0.23% | 00.0% | Unchanged |
| FCPM III Services B.V. | 3,468,430 | $14.7M | 1.96% | 00.0% | Unchanged |
| Armistice Capital, LLC | 3,398,000 | $14.4M | 0.40% | 00.0% | Unchanged |
| Long Focus Capital Management, LLC | 3,310,687 | $14.0M | 0.57% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 1,968,025 | $8.32M | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 1,533,400 | $6.50M | 0.01% | +554,100+56.6% | Added |
| GSK plc | 1,529,561 | $6.49M | 1.08% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 902,150 | $3.83M | 0.00% | −126,093−12.3% | Reduced |
| Marshall Wace, LLP | 797,940 | $3.38M | 0.00% | +420,605+111.5% | Added |
| Qube Research & Technologies Ltd | 775,567 | $3.29M | 0.00% | +466,950+151.3% | Added |